{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:55:05Z","timestamp":1790178905667,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":3317,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003549","name":"Orsz\u00e1gos Tudom\u00e1nyos Kutat\u00e1si Alapprogramok","doi-asserted-by":"publisher","award":["OTKA\u2010PD100245"],"award-info":[{"award-number":["OTKA\u2010PD100245"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003549","name":"Orsz\u00e1gos Tudom\u00e1nyos Kutat\u00e1si Alapprogramok","doi-asserted-by":"publisher","award":["OTKA\u2010K 109083"],"award-info":[{"award-number":["OTKA\u2010K 109083"]}],"id":[{"id":"10.13039\/501100003549","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) has a great epidemiological burden. The pathophysiological role of cyclic guanosine monophosphate (cGMP) signalling has been intensively investigated in HFpEF. Elevated levels of cGMP have been shown to exert cardioprotective effects in various cardiovascular diseases, including diabetic cardiomyopathy. We investigated the effect of long-term preventive application of the phosphodiesterase-5A (PDE5A) inhibitor vardenafil in diabetic cardiomyopathy-associated HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Zucker diabetic fatty (ZDF) rats were used as a model of HFpEF and ZDF lean rats served as controls. Animals received vehicle or 10 mg\/kg body weight vardenafil per os from weeks 7 to 32 of age. Cardiac function, morphology was assessed by left ventricular (LV) pressure\u2013volume analysis and echocardiography at week 32. Cardiomyocyte force measurements were performed. The key markers of cGMP signalling, nitro-oxidative stress, apoptosis, myocardial hypertrophy and fibrosis were examined. The ZDF animals showed diastolic dysfunction (increased LV\/cardiomyocyte stiffness, prolonged LV relaxation time), preserved systolic performance, decreased myocardial cGMP level coupled with impaired protein kinase G (PKG) activity, increased nitro-oxidative stress, enhanced cardiomyocyte apoptosis, and hypertrophic and fibrotic remodelling of the myocardium. Vardenafil effectively prevented the development of HFpEF by maintaining diastolic function (decreased LV\/cardiomyocyte stiffness and LV relaxation time), by restoring cGMP levels and PKG activation, by lowering apoptosis and by alleviating nitro-oxidative stress, myocardial hypertrophy and fibrotic remodelling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report that vardenafil successfully prevented the development of diabetes mellitus-associated HFpEF. Thus, PDE5A inhibition as a preventive approach might be a promising option in the management of HFpEF patients with diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.711","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T23:02:53Z","timestamp":1482188573000},"page":"326-336","source":"Crossref","is-referenced-by-count":88,"title":["Prevention of the Development of Heart Failure with Preserved Ejection Fraction by the Phosphodiesterase-5A Inhibitor Vardenafil in Rats with Type 2 Diabetes"],"prefix":"10.1093","volume":"19","author":[{"given":"Csaba","family":"M\u00e1ty\u00e1s","sequence":"first","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs T.","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Ol\u00e1h","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"T\u00f6r\u00f6k","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Ruppert","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalma","family":"Kellermayer","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint A.","family":"Barta","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, University of Heidelberg , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"K\u00f6k\u00e9ny","sequence":"additional","affiliation":[{"name":"Institute of Pathophysiology, Semmelweis University , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter M.","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Physiology, Semmelweis University , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Be\u00e1ta","family":"B\u00f3di","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology, Faculty of Medicine, University of Debrecen , Debrecen ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Papp","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology, Faculty of Medicine, University of Debrecen , Debrecen ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[{"name":"Experimental Research Laboratory, Heart and Vascular Center, Semmelweis University , V\u00e1rosmajor u. 68, 1122, Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,19]]},"reference":[{"key":"2026011721180683800_ejhf711-bib-0001","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026011721180683800_ejhf711-bib-0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/FJC.0b013e31829a4e61","article-title":"Heart failure with preserved ejection fraction: emerging drug strategies","volume":"62","author":"Zouein","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026011721180683800_ejhf711-bib-0003","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol Ther"},{"key":"2026011721180683800_ejhf711-bib-0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yjmcc.2016.01.004","article-title":"Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network","volume":"91","author":"Zhao","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"2026011721180683800_ejhf711-bib-0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12933-015-0309-x","article-title":"The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus","volume":"14","author":"Matyas","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2026011721180683800_ejhf711-bib-0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol Ther"},{"key":"2026011721180683800_ejhf711-bib-0007","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"key":"2026011721180683800_ejhf711-bib-0008","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"2026011721180683800_ejhf711-bib-0009","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"key":"2026011721180683800_ejhf711-bib-0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ejcts.2009.03.065","article-title":"Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass","volume":"36","author":"Szabo","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026011721180683800_ejhf711-bib-0011","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/TP.0b013e31818aa34e","article-title":"Effects of selective phosphodiesterase-5-inhibition on myocardial contractility and reperfusion injury after heart transplantation","volume":"86","author":"Loganathan","year":"2008","journal-title":"Transplantation"},{"key":"2026011721180683800_ejhf711-bib-0012","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1476-5381.2008.00098.x","article-title":"The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus","volume":"156","author":"Radovits","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2026011721180683800_ejhf711-bib-0013","doi-asserted-by":"crossref","first-page":"H1661","DOI":"10.1152\/ajpheart.01239.2009","article-title":"Defects in oxygen supply to skeletal muscle of prediabetic ZDF rats","volume":"298","author":"Ellis","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721180683800_ejhf711-bib-0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12471-016-0815-9","article-title":"Animal models of heart failure with preserved ejection fraction","volume":"24","author":"Conceicao","year":"2016","journal-title":"Neth Heart J"},{"key":"2026011721180683800_ejhf711-bib-0015","doi-asserted-by":"crossref","first-page":"H124","DOI":"10.1152\/ajpheart.00108.2013","article-title":"Rat model of exercise-induced cardiac hypertrophy: hemodynamic characterization using left ventricular pressure\u2013volume analysis","volume":"305","author":"Radovits","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721180683800_ejhf711-bib-0016","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.bbadis.2014.06.030","article-title":"Interplay of oxidative, nitrosative\/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy","volume":"1852","author":"Varga","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2026011721180683800_ejhf711-bib-0017","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2013.04.012","article-title":"Vascular dysfunction induced by hypochlorite is improved by the selective phosphodiesterase-5-inhibitor vardenafil","volume":"710","author":"Radovits","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"2026011721180683800_ejhf711-bib-0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yjmcc.2003.11.001","article-title":"Cardioprotection with phosphodiesterase-5 inhibition \u2013 a novel preconditioning strategy","volume":"36","author":"Kukreja","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"2026011721180683800_ejhf711-bib-0019","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"RELAX Trial Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"2026011721180683800_ejhf711-bib-0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12471-016-0812-z","article-title":"The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction","volume":"24","author":"Franssen","year":"2016","journal-title":"Neth Heart J"},{"key":"2026011721180683800_ejhf711-bib-0021","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","article-title":"Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging","volume":"125","author":"Giannetta","year":"2012","journal-title":"Circulation"},{"key":"2026011721180683800_ejhf711-bib-0022","doi-asserted-by":"crossref","first-page":"H1558","DOI":"10.1152\/ajpheart.00865.2013","article-title":"Chronic inhibition of phosphodiesterase 5 with tadalafil attenuates mitochondrial dysfunction in type 2 diabetic hearts: potential role of NO\/SIRT1\/PGC-1alpha signaling","volume":"306","author":"Koka","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011721180683800_ejhf711-bib-0023","doi-asserted-by":"crossref","first-page":"728741","DOI":"10.1155\/2015\/728741","article-title":"An altered pattern of myocardial histopathological and molecular changes underlies the different characteristics of type-1 and type-2 diabetic cardiac dysfunction","volume":"2015","author":"Radovits","year":"2015","journal-title":"J Diabetes Res"},{"key":"2026011721180683800_ejhf711-bib-0024","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026011721180683800_ejhf711-bib-0025","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026011721180683800_ejhf711-bib-0026","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1152\/physrev.00029.2006","article-title":"Nitric oxide and peroxynitrite in health and disease","volume":"87","author":"Pacher","year":"2007","journal-title":"Physiol Rev"},{"key":"2026011721180683800_ejhf711-bib-0027","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ceca.2014.09.005","article-title":"Regulation of SERCA pumps expression in diabetes","volume":"56","author":"Zarain-Herzberg","year":"2014","journal-title":"Cell Calcium"},{"key":"2026011721180683800_ejhf711-bib-0028","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.niox.2010.08.004","article-title":"Hemodynamic effects of inducible nitric oxide synthase inhibition combined with sildenafil during acute pulmonary embolism","volume":"23","author":"Dias-Junior","year":"2010","journal-title":"Nitric Oxide"},{"key":"2026011721180683800_ejhf711-bib-0029","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00395-008-0715-2","article-title":"Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy","volume":"103","author":"Van Linthout","year":"2008","journal-title":"Basic Res Cardiol"},{"key":"2026011721180683800_ejhf711-bib-0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy","volume":"11","author":"Takimoto","year":"2005","journal-title":"Nat Med"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.711","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/3\/326\/66331059\/eurjhf_19_3_326.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/19\/3\/326\/66331059\/eurjhf_19_3_326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T02:19:28Z","timestamp":1768702768000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/19\/3\/326\/8418840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,19]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,12,19]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.711","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,3]]},"published":{"date-parts":[[2016,12,19]]}}}